- Home
- TRDA
as 02-21-2025 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 502.9M | IPO Year: | 2021 |
| Target Price: | $25.67 | AVG Volume (30 days): | 96.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.35 - $21.79 | Next Earning Date: | 03-12-2025 |
| Revenue: | $215,232,000 | Revenue Growth: | 146.92% |
| Revenue Growth (this year): | 47.45% | Revenue Growth (next year): | -74.94% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | TRDA | 10% Owner | Dec 10 '24 | Sell | $20.50 | 44,722 | $917,110.96 | 4,402,849 | |
| MPM BioVentures 2014, L.P. | TRDA | 10% Owner | Dec 10 '24 | Sell | $20.50 | 44,722 | $917,110.96 | 4,402,849 | |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 29 '24 | Sell | $19.98 | 6,000 | $119,948.30 | 73,849 | |
| Sethuraman Natarajan | TRDA | President, Research & Develop. | Nov 29 '24 | Sell | $20.14 | 15,891 | $320,619.70 | 160,788 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now
Clinical Trials Arena
18 days ago
Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment
MT Newswires
19 days ago
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment
GlobeNewswire
19 days ago
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
PR Newswire
23 days ago
Azenta Announces the Election of Dipal Doshi to its Board of Directors
Simply Wall St.
a month ago
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Zacks
2 months ago
Best Momentum Stocks to Buy for December 30th
GlobeNewswire
2 months ago
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.